# Impeto Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/impeto-medical

- Industry: Medical Devices & Equipment
- Headquarters: Paris, France
- Website: www.impeto-medical.com
- Total disclosed funding: $8M
- Latest round: Series B (Jul 29, 2013)
- Investors on record: 3

## About

Impeto Medical specializes in the development and commercialization of medical devices aimed at the early detection and management of autonomic and small fiber neuropathies, primarily through its flagship product, SUDOSCAN.Founded in 2005 and headquartered in Paris, France, Impeto Medical focuses on innovating medical devices for nerve evaluation. The company was acquired in January 2022 by Withings SACA from Oddo BHF Private Assets and Seventure Partners. The acquisition presents opportunities to enhance the Sudoscan technology, both domestically and internationally. Philippe Brunswick, the CEO, has previously led endeavors in the healthcare sector, contributing to the company's vision.Impeto Medical’s primary product offering is the SUDOSCAN device, an innovative medical device designed for the early detection and management of autonomic and small fiber neuropathies. This system functions by stimulating sweat glands to evaluate small nerve fibers within the peripheral nervous system, providing an accurate assessment of sudomotor function in under three minutes. The device employs a computer interface alongside four electrodes where patients place their hands and bare feet to facilitate the test. SUDOSCAN is utilized in various clinical settings, particularly in diabetes management, oncology for quantifying chemotherapy-induced polyneuropathy, and nephrology for monitoring peripheral autonomic neuropathies. The company serves a global market, with its devices sold in over 34 countries, including the United States, France, Germany, and regions in Latin America, targeting healthcare professionals who require advanced diagnostic tools for managing patient outcomes in neurological and diabetic conditions.Impeto Medical generates revenue through the sales of its SUDOSCAN devices, which are classified as Class IIa medical devices and cleared for use by the FDA and CE certified. The company engages in direct sales to healthcare facilities, clinics, and hospitals, where practitioners utilize the SUDOSCAN device for patient evaluations and follow-ups. The revenue model is primarily based on one-time purchases of the device, with potential recurring revenue from consumables or maintenance agreements. Additionally, partnerships with healthcare organizations and distribution agreements in various international markets enhance the company’s reach and profitability. Specific pricing structures for the devices and associated services are determined based on market demand and regional pricing strategies, ensuring that SUDOSCAN meets the needs of its diverse client base.Impeto Medical plans to leverage the recent acquisition by Withings to further develop the SUDOSCAN technology, enhancing its capabilities and expanding its market presence. The company is targeting additional international markets for its SUDOSCAN device, with a focus on regions not yet fully penetrated. Recent funding from the Series B round, which raised EUR 1.147 mn, will be allocated to support these growth initiatives, enhancing product development and market outreach strategies.

## Funding rounds

- Series B, Jul 29, 2013, $1.5M — Idinvest Partners, Seventure Partners
- Series B, Jan 19, 2011, $6.5M — Seventure Partners, Oddo BHF Private Assets

## Investors

- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B
- Oddo BHF Private Assets (https://capitalatlas.ai/funds/oddo-bhf-private-assets) — Series B
- Idinvest Partners (https://capitalatlas.ai/funds/idinvest-partners) — Series B